Mymetics is focused on two pathways to develop prophylactic vaccines:
- The ability to build a first line of defence against viruses entering the blood stream by focusing on the mucosal layer.
- The development of a new vaccine delivery platform that does not use live attenuated or killed pathogens, while increasing the immunogenicity and stability of the vaccine.
Using these two pathways, our pipeline comprises vaccine candidates at various stages of clinical development.
Our vaccine candidates for HIV/AIDS, malaria and the intra-nasal influenza are based upon the influenza virosomes, thereby using the influenza virosome as the carrier. While the RSV vaccine candidate is based on their own natural virus and used directly as the vaccine.
